DelNova’s partnership will enable clinical development of its lead candidate ReViVox® for the rescue of undesirable outcomes which may arise from a botulinum neurotoxin (BoNT) treatment such as Botox®. Pace® Life Sciences provides a full suite of contract CMC development, clinical trials materials manufacturing, and regulatory compliance, services to the biopharmaceutical industries.
SAN DIEGO, Oct. 4, 2023 /PRNewswire/ — DelNova announces their partnership with Pace® Life Sciences as their intended (CDMO)contract development and manufacturing organization. This relationship supports DelNova’s plan to deliver its candidate Rescue Drug, ReViVox®, to resolve unwanted side-effects which may arise following Botulinum Neurotoxin (BoNT) therapy. BoNTs include US brands such as BOTOX®, DYSPORT®, XEOMIN® AND JEUVEAU®.
Pace® Life Sciences offers the expertise essential to complete the IND (investigational new drug)- enabling research for the future FDA submissions including formulation, kinetics, and stability.
Read full article here.